Methods are provided for predicting the presence, subtype and stage of ovarian cancer, as well as for assessing the therapeutic efficacy of a cancer treatment and determining whether a subject potentially is developing cancer. Associated test kits, computer and analytical systems as well as software
Methods are provided for predicting the presence, subtype and stage of ovarian cancer, as well as for assessing the therapeutic efficacy of a cancer treatment and determining whether a subject potentially is developing cancer. Associated test kits, computer and analytical systems as well as software and diagnostic models are also provided.
대표청구항▼
1. A set of reagents to measure the levels of biomarkers in a specimen, wherein the biomarkers are selected from the group consisting of the following panels of biomarkers or measurable fragments thereof: (a) myoglobin, CRP, FGF basic protein and CA 19-9;(b) Hepatitis C NS4, Ribosomal P Antibody and
1. A set of reagents to measure the levels of biomarkers in a specimen, wherein the biomarkers are selected from the group consisting of the following panels of biomarkers or measurable fragments thereof: (a) myoglobin, CRP, FGF basic protein and CA 19-9;(b) Hepatitis C NS4, Ribosomal P Antibody and CRP;(c) CA 19-9, TGF alpha, EN-RAGE, EGF and HSP 90 alpha antibody,(d) EN-RAGE, EGF, CA 125, Fibrinogen, Apolipoprotein CIII, Cholera Toxin and CA 19-9;(e) Proteinase 3 (cANCA) antibody, Fibrinogen, CA 125, EGF, CD40, TSH, Leptin, CA 19-9 and lymphotactin;(f) CA125, EGFR, CRP, IL-18, Apolipoprotein CIII, Tenascin C and Apolipoprotein A1;(g) CA125, Beta-2 Microglobulin, CRP, Ferritin, TIMP-1, Creatine Kinase-MB and IL-8;(h) CA125, EGFR, IL-10, Haptoglobin, CRP, Insulin, TIMP-1, Ferritin, Alpha-2 Macroglobulin, Leptin, IL-8, CTGF, EN-RAGE, Lymphotactin, TNF-alpha, IGF-1, TNF RII, von Willebrand Factor and MDC;(i) CA-125, CRP, EGF-R, CA-19-9, MIP-1, IL-18 and VCAM-1;j) CA-125, CRP, EGF-R, CA-19-9, MIP-1, vWF and VCAM-1;(k) CA-125, CRP, EGF-R, CA-19-9, Serum Amyloid P, IL-6 and MIP-1;(1) CA-125, CRP, EGF-R, CA-19-9, IL-6, MIP-1 and vWF;(m) CA-125, CRP, EGF-R, CA-19-9, Serum Amyloid P, ApoCIII and IL-18;(n) CA-125, CRP, EGF-R, CA-19-9, Apo A1, MIP-1 and vWF;(o) CA-125, CRP, EGF-R, CA-19-9, Serum Amyloid P, Apo A1, and MIP-1;(p) CA-125, CRP, EGF-R, IL-6, myoglobin, MIP-1 and myeloperoxidase;(q) CA-125, CRP, EGF-R, CA-19-9, myoglobin MIP-1 and Growth Hormone;(r) CA-125, CRP, EGF-R, CA-19-9, MIP-1, Growth Hormone and myeloperoxidase;(s) CA-125, CRP, EGF-R, CA-19-9, MIP-1, Growth Hormone and IL-18;(t) CA-125, CRP, EGF-R, CA-19-9, myoglobin, Growth Hormone and VCAM-1;(u) CA-125, CRP, EGF-R, CA-19-9, myoglobin, MIP-1 and Leptin;(v) CA-125, CRP, EGF-R, CA-19-9, myoglobin, Leptin and Growth Hormone;(w) CA-125, CRP, EGF-R, CA-19-9, IL-6, myoglobin and Growth Hormone;(x) CA-125, CRP, EGF-R, CA-19-9, myoglobin, Leptin and myeloperoxidase;(y) CA-125, CRP, EGF-R, CA-19-9, myoglobin, MIP-1 and insulin;(z) CA-125, CRP, EGF-R, CA-19-9, myoglobin, MIP-1 and ferritin;(aa) CA-125, CRP, EGF-R, CA-19-9, myoglobin, MIP-1 and myeloperoxidase;(bb) CA-125, CRP, EGF-R, CA-19-9, Serum Amyloid P, myoglobin, and MIP-1;(cc) CA-125, CRP, EGF-R, CA-19-9, myoglobin, MIP-1 and haptoglobulin;(dd) CA-125, CRP, EGF-R, CA-19-9, ApoA1, myoglobin, MIP-1 and leptin;(ee) CA-125, CRP, EGF-R, CA-19-9, IL-6, vWF and ApoCIII;(ff) CA-125, CRP, EGF-R, Serum Amyloid P, IL-6, MIP-1 and ferritin;(gg) CA-125, CRP, EGF-R, CA-19-9, vWF, ApoCIII and ferritin;(hh) CA-125, CRP, EGF-R, CA-19-9, IL-6, MIP-1 and ferritin;(ii) CA-125, CRP, EGF-R, CA-19-9, MIP-1, vWF and ApoCIII;(jj) CA-125, CRP, EGF-R, CA-19-9, Serum Amyloid P, ApoCIII and ferritin;(kk) CA-125, CRP, EGF-R, CA-19-9, IL-6, CK-MB and vWF; and(ll) CA-125, CRP, EGF-R, CA-19-9, MIP-1, IL-10 and ferritin. 2. The set of reagents of claim 1, wherein the reagents are binding molecules. 3. The set of reagents of claim 2, wherein the binding molecules are antibodies. 4. A test kit comprising the set of reagents of claim 1. 5. A multianalyte panel assay comprising the set of reagents of claim 1. 6. A method of predicting the likelihood of cancer in a subject, comprising: detecting the levels of biomarkers in a specimen using the set of reagents of claim 1, wherein a change in the levels of the biomarkers, as compared with a control group of patients who do not have cancer, is predictive of cancer in that subject. 7. The method of claim 6, wherein the cancer is ovarian cancer. 8. The method of claim 7, wherein a change in the relative levels of the biomarkers is determined. 9. The method of claim 7, wherein the specimen is selected from the group consisting of blood, serum, plasma, lymph, cerebrospinal fluid, ascites, urine and tissue biopsy. 10. The method of claim 7, wherein the ovarian cancer is selected from the group consisting of serous, endometrioid, mucinous, and clear cell cancer. 11. The method of claim 7, wherein the prediction of ovarian cancer includes a stage selected from the group consisting of Stage IA, IB, IC, II, III and IV tumors. 12. The method of claim 7, further comprising creating a report of the relative levels of the biomarkers. 13. The method of claim 12, wherein the report includes the prediction as to the presence or absence of ovarian cancer in the subject or the stratified risk of ovarian cancer for the subject, optionally by stage of cancer. 14. The method of claim 7, wherein the sample is taken from a subject selected from the group consisting of subjects who are symptomatic for ovarian cancer and subjects who are at high risk for ovarian cancer. 15. The method of claim 7, wherein the method has a sensitivity of at least about 85 percent and a specificity of at least about 85 percent. 16. The method of claim 15, wherein the sensitivity and specificity are determined for a population of women who are symptomatic for ovarian cancer and have ovarian cancer as compared with a control group of women who are symptomatic for ovarian cancer but who do not have ovarian cancer. 17. A predictive or diagnostic model based on levels of the panels of biomarkers of claim 1. 18. A method to assess the therapeutic efficacy of a cancer treatment, comprising: comparing the biomarker profiles in specimens taken from a subject before and after the treatment or during the course of treatment with a set of reagents according to claim 1, wherein a change in the biomarker profile over time toward a non-cancer profile or to a stable profile is interpreted as efficacy. 19. A method for determining whether a subject potentially is developing cancer, comprising: comparing the biomarker profiles in specimens taken from a subject at two or more points in time with a set of reagents according to claim 1, wherein a change in the biomarker profile toward a cancer profile, is interpreted as a progression toward developing cancer. 20. A set of antibodies fixed to a microsphere to measure the levels of biomarkers in a specimen, wherein the biomarkers are selected from the group consisting of the following panels of biomarkers and their measurable fragments: (a) myoglobin, CRP, FGF basic protein and CA 19-9;(b) Hepatitis C NS4, Ribosomal P Antibody and CRP;(c) CA 19-9, TGF alpha, EN-RAGE, EGF and HSP 90 alpha antibody;(d) EN-RAGE, EGF, CA 125, Fibrinogen, Apolipoprotein CIII, Cholera Toxin and CA 19-9;(e) Proteinase 3 (cANCA) antibody, Fibrinogen, CA 125, EGF, CD40, TSH, Leptin, CA 19-9 and lymphotactin;(f) CA125, EGFR, CRP, IL-18, Apolipoprotein CIII, Tenascin C and Apolipoprotein A1;(g) CA125, Beta-2 Microglobulin, CRP, Ferritin, TIMP-1, Creatine Kinase-MB and IL-8;(h) CA125, EGFR, IL-10, Haptoglobin, CRP, Insulin, TIMP-1, Ferritin, Alpha-2 Macroglobulin, Leptin, IL-8, CTGF, EN-RAGE, Lymphotactin, TNF-alpha, IGF-1, TNF RII, von Willebrand Factor and MDC;(i) CA-125, CRP, EGF-R, CA-19-9, MIP-1, IL-18 and VCAM-1;(j) CA-125, CRP, EGF-R, CA-19-9, MIP-1, vWF and VCAM-1;(k) CA-125, CRP, EGF-R, CA-19-9, Serum Amyloid P, IL-6 and MIP-1;(l) CA-125, CRP, EGF-R, CA-19-9, IL-6, MIP-1 and vWF;(m) CA-125, CRP, EGF-R, CA-19-9, Serum Amyloid P, ApoCIII and IL-18;(n) CA-125, CRP, EGF-R, CA-19-9, Apo A1, MIP-1 and vWF;(o) CA-125, CRP, EGF-R, CA-19-9, Serum Amyloid P, Apo A1, and MIP-1;(p) CA-125, CRP, EGF-R, IL-6, myoglobin, MIP-1 and myeloperoxidase;(q) CA-125, CRP, EGF-R, CA-19-9, myoglobin, MIP-1 and Growth Hormone;(r) CA-125, CRP, EGF-R, CA-19-9, MIP-1, Growth Hormone and myeloperoxidase;(s) CA-125, CRP, EGF-R, CA-19-9, MIP-1, Growth Hormone and IL-18;(t) CA-125, CRP, EGF-R, CA-19-9, myoglobin, Growth Hormone and VCAM-1;(u) CA-125, CRP, EGF-R, CA-19-9, myoglobin, MIP-1 and Leptin;(v) CA-125, CRP, EGF-R, CA-19-9, myoglobin, Leptin and Growth Hormone;(w) CA-125, CRP, EGF-R, CA-19-9, IL-6, myoglobin and Growth Hormone;(x) CA-125, CRP, EGF-R, CA-19-9, myoglobin, Leptin and myeloperoxidase;(y) CA-125, CRP, EGF-R, CA-19-9, myoglobin, MIP-1 and insulin;(z) CA-125, CRP, EGF-R, CA-19-9, myoglobin, MIP-1 and ferritin;(aa) CA-125, CRP, EGF-R, CA-19-9, myoglobin, MIP-1 and myeloperoxidase;(bb) CA-125, CRP, EGF-R, CA-19-9, Serum Amyloid P, myoglobin, and MIP-1;(cc) CA-125, CRP, EGF-R, CA-19-9, myoglobin, MIP-1 and haptoglobulin;(dd) CA-125, CRP, EGF-R, CA-19-9, ApoA1, myoglobin, MIP-1 and leptin;(ee) CA-125, CRP, EGF-R, CA-19-9, IL-6, vWF and ApoCIII;(ff) CA-125, CRP, EGF-R, Serum Amyloid P, IL-6, MIP-1 and ferritin;(gg) CA-125, CRP, EGF-R, CA-19-9, vWF, ApoCIII and ferritin;(hh) CA-125, CRP, EGF-R, CA-19-9, IL-6, MIP-1 and ferritin;(ii) CA-125, CRP, EGF-R, CA-19-9, MIP-1, vWF and ApoCIII;(jj) CA-125, CRP, EGF-R, CA-19-9, Serum Amyloid P, ApoCIII and ferritin;(kk) CA-125, CRP, EGF-R, CA-19-9, IL-6, CK-MB and vWF; and(ll) CA-125, CRP, EGF-R, CA-19-9, MIP-1, IL-10 and ferritin.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (56)
Bowman-Amuah, Michel K., Abstraction factory in a base services pattern environment.
Holland John H. (3800 W. Huron River Dr. Ann Arbor MI 48103) Burks Arthur W. (3445 Vintage Valley Rd. Ann Arbor MI 48105), Adaptive computing system capable of learning and discovery.
Castleman ; Kenneth R. ; Frieden ; Howard J. ; Johnson ; Elbert T. ; Re nnie ; Paul A. ; Wall ; Raymond J., Automated clinical system for chromosome analysis.
Ham Fredric M. (Indialantic FL) Cohen Glenn M. (Indialantic FL), Determination of concentrations of biological substances using raman spectroscopy and artificial neural network discrimi.
Dasseux, Jean-Louis H.; Newton, Roger S.; Rea, Thomas J.; Bisgaier, Charles L.; Pape, Michael E., Fourier transform mass spectrometry of complex biological samples.
Hazlehurst Brian L. ; Burke Scott M. ; Nybakken Kristopher E., Intelligent query system for automatically indexing information in a database and automatically categorizing users.
Kohl Matthias,GB3 ; Cope Mark,GB3 ; Essenpreis Matthias,DEX ; Boecker Dirk,DEX, Method and apparatus for determining analytical data concerning the inside of a scattering matrix.
Risby ; Terence H. ; Yergey ; III ; Alfred L., Method to generate correlative data from various products of thermal degradation of biological specimens.
Agrafiotis, Dimitris K.; Lobanov, Victor S.; Salemme, Francis R., Method, system and computer program product for non-linear mapping of multi-dimensional data.
Agrafiotis Dimitris K. ; Lobanov Victor S. ; Salemme Francis R., Method, system, and computer program product for representing similarity/dissimilarity between chemical compounds.
Heller Michael J. (Encinitas CA) Tu Eugene (San Diego CA) Butler William F. (Carlsbad CA), Molecular biological diagnostic systems including electrodes.
Koza John R. (25372 La Rena La. Los Altos Hills CA 94022), Non-linear genetic algorithms for solving problems by finding a fit composition of functions.
Veltri Robert W ; Bacus Michael P. ; Miller M. Craig ; Ashenayi Kaveh ; Coffey Donald P. ; Partin Alan W. ; Epstein Jonathan I., Prediction of prostate cancer progression by analysis of selected predictive parameters.
Hitt, Ben A.; Petricoin, III, Emanuel F.; Levine, Peter J.; Liotta, Lance A., Process for discriminating between biological states based on hidden patterns from biological data.
Risby ; Terence H. ; Yergey ; III ; Alfred L., Programmed thermal degradation-mass spectrometry analysis method facilitating identification of a biological specimen.
Kaufmann Peter (Mossvagen 56 Jarna SEX 153 37 ) Beving Hkan (Linnegatan 33-35 Stockholm SEX 114 47 ) Olsson Nils U. (6829 Acacia Ct. Frederick MD 21703), Selective differentiating diagnostic process based on broad data bases.
Miller,Raanan A.; Nazarov,Erkinjon G.; Zapata,Angela; Davis,Cristina E.; Eiceman,Gary A.; Bashall,Anthony D., Systems for differential ion mobility analysis.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.